• Applied Biosystems (Carlsbad, California) reported the expansion of its portfolio of capillary electrophoresis sequencing systems with the introduction of two new lines of genetic analyzers. The 3500 Dx Series Genetic Analyzers are intended for use in the analysis of human DNA or RNA for the detection of genetic changes that may lead to disease presence or susceptibility. Both platforms will provide advancements in CE sequencing systems, setting significant new standards for throughput, data quality and ease of use.

• Competitive Technologies (CTI; Fairfield, Connecticut) said its pain therapy medical device will be used by clinical investigators at the Virginia Commonwealth University Massey Cancer Center (Richmond) for a Phase II independent clinical study. The study will examine the ability of the FDA-cleared device to decrease pain associated with chemotherapy-induced peripheral neuropathy (CIPN). Massey is the first site in the U.S. to offer a clinical study for pain in cancer patients with this device. The device is a non-invasive method for rapid treatment of high-intensity oncologic and neuropathic pain, including pain resistant to morphine and other drugs.

• Qiagen (Venlo, the Netherlands) reported the launch of a novel product for extraction of free circulating fragments of tumor- and fetal-derived nucleic acids as well as viral nucleic acids in human blood. Scientists consider these DNA and RNA fragments to have great potential for the highly sensitive and non-invasive diagnosis of a wide range of diseases, including congenital disorders, malignancies such as colon and lung cancer, and infections. The QIAamp Circulating Nucleic Acid Kit enables the isolation and purification of all types and all sizes of nucleic acids from large-scale plasma and serum samples – and thereby enables unprecedented yields of the isolated molecules and the highest sensitivity of downstream applications.

• Rafael Medical Technologies (Dover, Delaware) has received FDA approval for its SafeFlo Vena Cava Filter. The approval is for the permanent implantation of the filter in patients at risk of pulmonary embolism; safety and effectiveness as a retrievable or temporary filter have not been established. The SafeFlo filter is an implanted expandable metal device used to capture hazardous blood clots caused by trauma, surgery or other medical conditions before they can reach the lungs, causing a pulmonary embolism.